NASDAQ:BJDX Bluejay Diagnostics (BJDX) Stock Forecast, Price & News $4.29 -0.43 (-9.11%) (As of 10:21 AM ET) Add Compare Share Share Today's Range$4.20▼$4.8850-Day Range$3.06▼$8.8252-Week Range$2.90▼$18.91Volume74,130 shsAverage Volume435,396 shsMarket Capitalization$4.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bluejay Diagnostics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy9.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.89) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.78 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Bluejay Diagnostics. Previous Next 4.0 Short Interest Percentage of Shares Shorted9.18% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently decreased by 22.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBluejay Diagnostics does not currently pay a dividend.Dividend GrowthBluejay Diagnostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BJDX. Previous Next 2.5 News and Social Media Coverage News SentimentBluejay Diagnostics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bluejay Diagnostics this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for BJDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Bluejay Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders47.00% of the stock of Bluejay Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.52% of the stock of Bluejay Diagnostics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bluejay Diagnostics are expected to grow in the coming year, from ($4.89) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bluejay Diagnostics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bluejay Diagnostics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBluejay Diagnostics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bluejay Diagnostics (NASDAQ:BJDX) StockBluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Read More BJDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BJDX Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comBluejay Diagnostics (NASDAQ:BJDX) Trading Down 0.6%September 20, 2023 | benzinga.comWhat's Going On With Bluejay Diagnostics Stock Today?September 22, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 12, 2023 | americanbankingnews.comBluejay Diagnostics (NASDAQ:BJDX) & OraSure Technologies (NASDAQ:OSUR) Head to Head ContrastAugust 28, 2023 | finance.yahoo.comBJDX: FDA Meeting Confirms PathwayAugust 16, 2023 | finanznachrichten.deBluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsAugust 16, 2023 | finance.yahoo.comBluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comBluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 22, 2023 | Legacy Research (Ad)Reverse ‘money machines’ popping up across AmericaIf you’ve been to a concert venue, stadium, or airport, you’ve almost certainly walked by one without knowing. The experts are calling it a 'Reverse ATM' Why are these machines suddenly appearing out of nowhere? And what does it mean for your money?August 3, 2023 | msn.comDawson James Downgrades Bluejay Diagnostics (BJDX)August 3, 2023 | msn.comBluejay Diagnostics (BJDX) Price Target Increased by 1900.00% to 61.20July 28, 2023 | benzinga.comWhat's Going On With BlueJay Diagnostics Stock?July 24, 2023 | marketwatch.comBluejay Diagnostics Shares Rise 82% After Reverse Stock SplitJuly 24, 2023 | finance.yahoo.comWill Bluejay Diagnostics (NASDAQ:BJDX) Spend Its Cash Wisely?July 21, 2023 | seekingalpha.comBluejay Diagnostics announces 1-for-20 reverse stock split to regain Nasdaq complianceJuly 21, 2023 | marketwatch.comBluejay Diagnostics Shares Rise 13% After Reverse Stock Split AnnouncedJuly 21, 2023 | finance.yahoo.comBluejay Diagnostics Announces Reverse Stock SplitJuly 7, 2023 | markets.businessinsider.comWhy Is Bluejay Diagnostics (BJDX) Stock Up 17% Today?May 31, 2023 | finance.yahoo.comBJDX: Orchestrating a New Testing StandardMay 19, 2023 | finance.yahoo.comBluejay Diagnostics Updates Symphony IL-6 Regulatory StrategyMay 12, 2023 | msn.comBluejay Diagnostics: Q1 Earnings InsightsMay 12, 2023 | marketwatch.com8-K: Bluejay Diagnostics, Inc.May 10, 2023 | seekingalpha.comBluejay Diagnostics GAAP EPS of -$0.12May 10, 2023 | finanznachrichten.deBluejay Diagnostics, Inc.: Bluejay Diagnostics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comBluejay Diagnostics Reports First Quarter 2023 Financial ResultsMay 7, 2023 | nypost.comUp In the Blue Seats PodcastMarch 21, 2023 | finanznachrichten.deBluejay Diagnostics, Inc.: Bluejay Diagnostics Reports 2022 Financial ResultsSee More Headlines Receive BJDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address BJDX Company Calendar Last Earnings8/14/2023Today9/22/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BJDX CUSIPN/A CIK1704287 Webwww.bluejaydx.com Phone844-327-7078FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,300,000.00 Net MarginsN/A Pretax Margin-3,945.38% Return on Equity-102.34% Return on Assets-86.12% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual Sales$250,000.00 Price / Sales19.26 Cash FlowN/A Price / Cash FlowN/A Book Value$11.45 per share Price / Book0.41Miscellaneous Outstanding Shares1,020,000Free Float542,000Market Cap$4.81 million OptionableNot Optionable Beta1.10 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Indranil Dey (Age 59)Pres, CEO & Director Comp: $413.16kMr. Kenneth R. Fisher CPA (Age 44)Chief Financial Officer Comp: $366.18kDr. Jason Cook (Age 40)Chief Technology Officer Comp: $278.42kMr. Les DeLucaVP of OperationsEryn GrahamMarketing Mang.Mr. Kevin Vance (Age 66)Chief Commercial Officer Mark W. FeinbergChief Medical AdvisorDr. Mark W. Feinberg M.D.Chief Medical AdvisorRyan McSeveneyCorp. ControllerMore ExecutivesKey CompetitorsIntelligent Bio SolutionsNASDAQ:INBSDynatronicsNASDAQ:DYNTInVivo TherapeuticsNASDAQ:NVIVINVO BioscienceNASDAQ:INVOPlus TherapeuticsNASDAQ:PSTVView All Competitors BJDX Stock - Frequently Asked Questions Should I buy or sell Bluejay Diagnostics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bluejay Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BJDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BJDX, but not buy additional shares or sell existing shares. View BJDX analyst ratings or view top-rated stocks. How have BJDX shares performed in 2023? Bluejay Diagnostics' stock was trading at $7.5980 at the beginning of the year. Since then, BJDX stock has decreased by 37.9% and is now trading at $4.72. View the best growth stocks for 2023 here. When is Bluejay Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our BJDX earnings forecast. How were Bluejay Diagnostics' earnings last quarter? Bluejay Diagnostics, Inc. (NASDAQ:BJDX) released its earnings results on Monday, August, 14th. The company reported ($2.75) earnings per share for the quarter, missing the consensus estimate of ($1.50) by $1.25. When did Bluejay Diagnostics' stock split? Bluejay Diagnostics's stock reverse split on Monday, July 24th 2023. The 1-20 reverse split was announced on Monday, July 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Bluejay Diagnostics IPO? (BJDX) raised $22 million in an initial public offering (IPO) on Wednesday, November 10th 2021. The company issued 2,160,000 shares at $10.00 per share. What is Bluejay Diagnostics' stock symbol? Bluejay Diagnostics trades on the NASDAQ under the ticker symbol "BJDX." How do I buy shares of Bluejay Diagnostics? Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bluejay Diagnostics' stock price today? One share of BJDX stock can currently be purchased for approximately $4.72. How much money does Bluejay Diagnostics make? Bluejay Diagnostics (NASDAQ:BJDX) has a market capitalization of $4.81 million and generates $250,000.00 in revenue each year. The company earns $-9,300,000.00 in net income (profit) each year or ($10.55) on an earnings per share basis. How can I contact Bluejay Diagnostics? The official website for the company is www.bluejaydx.com. The company can be reached via phone at 844-327-7078 or via email at ir@bluejaydx.com. This page (NASDAQ:BJDX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.